Lymphoma

In this video interview, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute discusses the use of cellular therapy in patients with relapsed/refractory Lymphoma.

In a video interview, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute discusses who benefits from awareness surrounding DLBCL.

The FDA granted accelerated approval to epcoritamab-bysp for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, according to the agent’s manufacturer.

Adolescent and young adult cancer survivors who received cardiotoxic treatments exhibited a high burden of poor cardiac function, according to study results presented at American Association for Cancer Research Annual Meeting.

Ten of 11 patients with relapsed or refractory B-cell lymphoma achieved objective response to an investigational dual-target chimeric antigen receptor T-cell therapy, according to study results.

A 56-year-old white man was referred to the uveitis clinic at the New England Eye Center by an outside ophthalmologist for sudden-onset painless vision loss that started 2 months before presentation.

The FDA approved polatuzumab vedotin-piiq in combination with rituximab, cyclophosphamide, doxorubicin and prednisone as first-line therapy for patients with certain types of B-cell lymphoma.

Cardiovascular disease, especially atherosclerotic CVD, was associated with increased risk for cancer diagnosis, according to a study published in JACC: CardioOncology.

Physicians recommended chimeric antigen receptor T-cell therapy more frequently than any other regimen for third-line treatment of relapsed or refractory diffuse large B-cell lymphoma, survey results showed.